Placebo (NNC0174-0833)

DRUG3 trials

Sponsors

Novo Nordisk A/S

Conditions

ObesityOverweight

Phase 1

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

CompletedNCT03600480

Novo Nordisk A/SObesity, Overweight

Start: 2018-07-25End: 2020-06-12Updated: 2021-11-17

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

CompletedNCT03787225

Novo Nordisk A/SObesity, Overweight

Start: 2019-01-07End: 2019-06-04Updated: 2019-06-24

Phase 2

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

CompletedNCT03856047

Novo Nordisk A/SObesity, Overweight

Start: 2019-03-01End: 2021-03-25Updated: 2024-07-05

Related Papers

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.

2021-11-16139 citations

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.

2021-04-22201 citations